热门资讯> 正文

Pacira与强生签署合作伙伴关系，扩大Zilretta

2025-07-22 20:52

Pacira BioSciences (NASDAQ:PCRX) said it has partnered with Johnson & Johnson MedTech (NYSE:JNJ) to enhance the availability of Zilretta, a treatment designed for knee pain caused by osteoarthritis.
This collaboration aims to utilize Johnson & Johnson's specialized sales team to promote Zilretta to both current and potential customers, the company said.
Zilretta is known for its extended-release formula that helps manage knee pain effectively.

More on Pacira BioSciences, Johnson & Johnson

Johnson & Johnson: The Worst Is Baked In
Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript
Johnson & Johnson 2025 Q2 - Results - Earnings Call Presentation
Johnson & Johnson seeks icotrokinra FDA approval
Former biotech exec George Tidmarsh to lead key FDA drug center

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。